(Reuters) – Britain’s GlaxoSmithKline (NYSE:) on Friday laid out plans to set up a new life sciences campus within its R&D site in Stevenage, England, raising 400 million pounds ($552.76 million) through the sale of some land at the facility.
The drugmaker said it expects to select a developer from the private sector later this year, and will begin work on the project in 2022.
($1 = 0.7236 pounds)
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Need Your Help Today. Your $1 can change life.